InnoCan Pharma (HAM:IP40) EPS without NRI: €-0.62 (TTM As of Mar. 2026)


HAM:IP40 InnoCan Pharma Corp HAM:IP40
59 GF Score
Price €1.80
GF Value €9.24
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is InnoCan Pharma EPS without NRI?

InnoCan Pharma HAM:IP40 +22.87% 59 EPS without NRI is €-0.62 as of Mar. 2026. GuruFocus rates HAM:IP40 with a GF Score™ of 59/100 and a GF Value™ of €9.24 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,520 Consumer Packaged Goods companies, InnoCan Pharma ranks better than 74.93% on this metric.

InnoCan Pharma's earnings per share without non-recurring items for the three months ended in Mar. 2026 was €-0.19. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.62.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 30.00% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 21.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for InnoCan Pharma's EPS without NRI or its related term are showing as below:

HAM:IP40' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -64.1   Med: 9.9   Max: 30
Current: 30

During the past 8 years, InnoCan Pharma's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 30.00% per year. The lowest was -64.10% per year. And the median was 9.90% per year.

HAM:IP40's 3-Year EPS without NRI Growth Rate is ranked better than
74.93% of 1520 companies
in the Consumer Packaged Goods industry
Industry Median: 7.45 vs HAM:IP40: 30.00

InnoCan Pharma's EPS (Diluted) for the three months ended in Mar. 2026 was €-0.19. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.33.

InnoCan Pharma's EPS (Basic) for the three months ended in Mar. 2026 was €-0.19. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.33.


InnoCan Pharma  (HAM:IP40) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


InnoCan Pharma EPS without NRI Related Terms


InnoCan Pharma EPS without NRI Historical Data

* Premium members only.

The historical data trend for InnoCan Pharma's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCan Pharma EPS without NRI Chart

InnoCan Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial -2.21 -1.41 -1.16 -1.03 -0.43

InnoCan Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.03 -0.27 -0.14 -0.19

HAM:IP40 vs PG, CL, KVUE: EPS without NRI Comparison

For the Household & Personal Products subindustry, InnoCan Pharma's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnoCan Pharma PE Ratio without NRI vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where InnoCan Pharma's PE Ratio without NRI falls into.


HAM:IP40
59GF Score
InnoCan Pharma Corp HAM:IP40
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InnoCan Pharma EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €-0.62 mean?
InnoCan Pharma (HAM:IP40) has a EPS without NRI of €-0.62 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on InnoCan Pharma and its competitors. According to the industry distribution chart, InnoCan Pharma ranks #381 out of 1520 companies in the Consumer Packaged Goods industry, placing it in the top 25.1%.
Is InnoCan Pharma's EPS without NRI too high?
InnoCan Pharma's current EPS without NRI is €-0.62. Based on the distribution chart, InnoCan Pharma ranks #381 out of 1520 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, InnoCan Pharma has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's EPS without NRI compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #381 out of 1520 companies for EPS without NRI. This puts InnoCan Pharma in the upper half of its industry. The industry median EPS without NRI is 7.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Consumer Packaged Goods company?
The median EPS without NRI among Consumer Packaged Goods companies is 7.45, based on 1,520 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on InnoCan Pharma and its competitors. For the Consumer Packaged Goods industry, the median EPS without NRI is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current EPS without NRI is €-0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (HAM:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €9.24, compared to a current price of €1.80 — trading 80.5% below its estimated fair value. The current EPS without NRI is €-0.62. InnoCan Pharma's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For InnoCan Pharma (HAM:IP40), the current EPS without NRI is €-0.62 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InnoCan Pharma (HAM:IP40) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued. The current stock price of €1.80 is trading 80.5% below its estimated GF Value™ of €9.24. GuruFocus considers InnoCan Pharma to be Possible Value Trap.

Key valuation signals for HAM:IP40:

  • EPS without NRI: €-0.62
  • GF Value™: €9.24 vs. price of €1.80 (80.5% below fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the HAM:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


InnoCan Pharma Business Description

Other Exchanges INNPF:USAINNO:Canada
Address 1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
59GF Score

Get the complete analysis for HAM:IP40

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.80
Price
€9.24
GF Value